Hologic, Inc. (NASDAQ:HOLX) is reporting fourth quarter earnings results on Wednesday 4th November 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 1.22 per share.
For the full year, analysts predict revenues of $ 3531.96 million, while looking forward to income of $ 3.12 per share.
The Company Outlook
Earnings for 4Q20 are anticipated in a range of $ 0.95 ~ $ 1.15 per share, while revenues are expected in a range of $ 1,225.00 million ~ $ 1,275.00 million
Full Year 2020 topline are forecasted in a range of$ 3,238.00 million ~ $ 3,268.00 million, where as bottomline are predicted in a range of $ 2.63 ~ $ 2.67 per share
Click Here For More Historical Outlooks Of Hologic, Inc.
Previous Quarter Performance
Hologic, Inc. unveiled income for the third quarter of $ 0.75 per share, from the revenue of $ 822.90 million. The quarterly earnings up 19.05 percent compared with the same quarter last year. Wall street analysts are predicting, HOLX to report 3Q20 income of $ 0.38 per share from revenue of $ 616.69 million. The bottom line results beat street analysts by $ 0.37 or 97.37 percent, at the same time, top line results outshined analysts by $ 206.21 million or 33.44 percent.
Stock Performance
Shares of Hologic, Inc. traded up $ 1.36 or 1.93 percent on Tuesday, reaching $ 71.92 with volume of 1.78 million shares. Hologic, Inc. has traded high as $ 72.18 and has cracked $ 70.48 on the downward trend
According to the previous trading day, closing price of $ 71.92, representing a 166.36 % increase from the 52 week low of $ 26.49 and a 4.17 % decrease over the 52 week high of $ 73.63.
The company has a market capital of $ 18.63 billion and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Hologic, Inc. will be hosting a conference call at 4:30 PM eastern time on 4th November 2020, to discuss its 4Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.hologic.com
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products.
